Skip to content

Renal ablation articles

Published December 30, 2019

  1. Fujimori, M, Yamanaka, T, Matsushita, N, Kishi, S, Nagata, C, Kato, H et al.. Long-term Clinical Outcomes of Radiofrequency Ablation for Pathologically Diagnosed T1a Renal Cell Carcinoma: A 10-Year Single-center Experience. Interv Radiol (Higashimatsuyama). 2026;11 :e20250113. doi: 10.22575/interventionalradiology.2025-0113. PubMed PMID:42445307 PubMed Central PMC13364337.
  2. Ferrillo, G, Baldassarre, E, Sirugo, T, Romano, S, Lanza, E, Poretti, D et al.. First report of safety and outcomes of radiofrequency ablation of renal tumors using a new automated energy delivery-controlled system. Minerva Urol Nephrol. 2026;78 (3):363-372. doi: 10.23736/S2724-6051.26.06732-7. PubMed PMID:42438982 .
  3. Iacovelli, R, Ciccarese, C, Arduini, D, Tagliaferri, L, Minervini, A, Simone, G et al.. The ITALIC-RCC: A Randomized Trial on Clinical and Humoral Impact of Primary Tumor Ablation by Surgery or Radiotherapy in Metastatic Renal Cell Carcinoma Treated with Checkpoint Inhibitors. Eur Urol Open Sci. 2026;90 :77-83. doi: 10.1016/j.euros.2026.06.004. PubMed PMID:42433301 PubMed Central PMC13351335.
  4. Borgbjerg, J, Kjærgård Nielsen, T, Graumann, O. Clarifying Recurrence, Bleeding Risk, and Procedural Burden in Central Renal Tumor Ablation. J Vasc Interv Radiol. 2026; :108947. doi: 10.1016/j.jvir.2026.108947. PubMed PMID:42409308 .
  5. Madoff, DC, Farhan, A. Reply to "Clarifying Recurrence, Bleeding Risk, and Procedural Burden in Central Renal Tumor Ablation". J Vasc Interv Radiol. 2026; :108948. doi: 10.1016/j.jvir.2026.108948. PubMed PMID:42401368 .
  6. Gan, J, Gan, J, Jiang, Y, Li, J, Yang, X, Deng, Z et al.. Percutaneous thermal ablation of the parathyroid glands is associated with short-term echocardiographic improvements in left ventricular structure and function in patients with end-stage renal disease and secondary hyperparathyroidism. Int J Hyperthermia. 2026;43 (1):2680506. doi: 10.1080/02656736.2026.2680506. PubMed PMID:42393012 .
  7. Gan, JX, Li, MF, Deng, HH, Liu, QT, Chen, ZX, Liang, CL et al.. Ablation of the renal tubular gluconeogenic enzyme PCK1 drives AKI-to-CKD transition by negatively regulating the TGF-β/Smad3 signaling pathway. Cell Mol Life Sci. 2026; :. doi: 10.1007/s00018-026-06310-1. PubMed PMID:42380498 .
  8. Schubert, O, Sighinolfi, MC, Gavi, F, Panio, E, Assumma, S, Silvestri, A et al.. Correction: Schubert et al. Minimally Invasive Ablation Strategies for Renal Cell Carcinoma Patients Ineligible for Surgery. Life 2026, 16, 73. Life (Basel). 2026;16 (6):. doi: 10.3390/life16060919. PubMed PMID:42355565 PubMed Central PMC13302591.
  9. Lucignani, G, Bigot, P, Roupret, M, Parier, B, Branger, N, Champy, C et al.. Partial Nephrectomy Versus Thermal Ablation for Cystic Renal Tumors: A Registry-Based, Propensity Score Matched Analysis (UroCCR n°177). Cardiovasc Intervent Radiol. 2026; :. doi: 10.1007/s00270-026-04482-8. PubMed PMID:42337129 .
  10. Yoo, YJ, Jiyoon, L, Park, KJ, Song, C, Kim, YJ, Kim, YS et al.. Oncologic outcomes and renal function preservation after stereotactic ablative body radiotherapy versus radiofrequency ablation in stage I renal cell carcinoma. Clin Transl Radiat Oncol. 2026;60 :101193. doi: 10.1016/j.ctro.2026.101193. PubMed PMID:42305853 PubMed Central PMC13266214.
  11. Hernández-Mancera, J, Remer, EM, Graumann, O, Borgbjerg, J. Image-guided percutaneous ablation techniques for the treatment of renal cell carcinoma: a primer for radiologists. Abdom Radiol (NY). 2026; :. doi: 10.1007/s00261-026-05589-9. PubMed PMID:42240648 .
  12. Levy, AP, Asleh, R. Haptoglobin, hemolysis, and renal vulnerability after pulsed field ablation: The hemoglobin-binding reserve. Heart Rhythm. 2026; :. doi: 10.1016/j.hrthm.2026.05.050. PubMed PMID:42235779 .
  13. Zorzi, F, Amodeo, A, Moretto, S, Ingels, A, Crestani, A, Di Gianfrancesco, L et al.. Percutaneous thermal ablation versus robot-assisted partial nephrectomy for localized renal cell carcinoma: a systematic review and meta-analysis stratified by tumor complexity. J Robot Surg. 2026;20 (1):. doi: 10.1007/s11701-026-03442-1. PubMed PMID:42223755 .
  14. Tanaka, Y, Takahashi, A, Yano, H, Kawaguchi, N, Nakashima, E, Okubo, K et al.. Association between baseline haptoglobin and early renal injury after pulsed-field ablation. Heart Rhythm. 2026; :. doi: 10.1016/j.hrthm.2026.05.026. PubMed PMID:42190927 .
  15. Singh, M, Saucedo, E, Schade, GR, Trivedi, V, Singh, AK, Shekhar, H et al.. Preclinical Assessment of an Image-Guided Histotripsy System for Renal Ablation. IEEE Trans Biomed Eng. 2026;PP :. doi: 10.1109/TBME.2026.3692044. PubMed PMID:42133509 .
  16. Saluja, S. A commentary on transvenous aorticorenal ganglion ablation: a leap towards physiology-guided renal denervation. J Hypertens. 2026;44 (6):948-949. doi: 10.1097/HJH.0000000000004251. PubMed PMID:42052882 .
  17. Bertolo, R, Puppini, G, Minervini, A, Rocco, B, Pettenuzzo, G, Antonelli, A et al.. Rethinking biopsy timing in renal mass ablation: aligning evolving guidelines with personalized care. Minerva Urol Nephrol. 2026;78 (2):285-287. doi: 10.23736/S2724-6051.26.06985-5. PubMed PMID:42023751 .
  18. Marey, A, Elkeden, H, Alrohaibani, Y, Khalaf, M, Karam, JA, Matin, S et al.. Percutaneous ablation of T1b renal tumors: a review. Cancer Imaging. 2026;26 (1):. doi: 10.1186/s40644-026-01030-y. PubMed PMID:41998698 PubMed Central PMC13224444.
  19. McMaster, T, Fay, T, Homewood, D, Neerhut, T, Perumalla, V, Perumalla, C et al.. Laparoscopic Partial Nephrectomy Versus Microwave Ablation in the Treatment of Renal Masses. ANZ J Surg. 2026;96 (6):1521-1527. doi: 10.1111/ans.70678. PubMed PMID:41992611 .
  20. Melenovský, V, Hozman, M, Hassouna, S, Fišerová, I, Bačová, B, Heřman, D et al.. A Comprehensive Assessment of Renal Function During and After Pulsed Field Ablation. J Cardiovasc Electrophysiol. 2026;37 (6):1259-1267. doi: 10.1111/jce.70281. PubMed PMID:41981834 PubMed Central PMC13269865.
Search PubMed

Published in Uncategorized